

## DESCRIPTION

<b>Species Reactivity</b>	Mouse
<b>Specificity</b>	Detects mouse Fc $\gamma$ RII/RIII (CD32/CD16) in direct ELISAs and Western blots. In direct ELISAs and Western blots, 100% cross-reactivity with recombinant mouse CD16 is observed and no cross-reactivity with recombinant human CD32 is observed.
<b>Source</b>	Monoclonal Rat IgG <sub>2B</sub> Clone # 190909
<b>Purification</b>	Protein A or G purified from hybridoma culture supernatant
<b>Immunogen</b>	Mouse myeloma cell line NS0-derived recombinant mouse Fc $\gamma$ RIIB Thr30-Arg207 Accession # P08101
<b>Formulation</b>	Lyophilized from a 0.2 $\mu$ m filtered solution in PBS with Trehalose. See Certificate of Analysis for details. *Small pack size (-SP) is supplied as a 0.2 $\mu$ m filtered solution in PBS.

## APPLICATIONS

**Please Note:** Optimal dilutions should be determined by each laboratory for each application. *General Protocols* are available in the *Technical Information* section on our website.

	Recommended Concentration	Sample
<b>Western Blot</b>	1 $\mu$ g/mL	Recombinant Mouse Fc $\gamma$ RIIB/CD32b (Catalog # 1460-CD)
<b>Flow Cytometry</b>	2.5 $\mu$ g/10 <sup>6</sup> cells	Mouse splenocytes

## PREPARATION AND STORAGE

<b>Reconstitution</b>	Reconstitute at 0.5 mg/mL in sterile PBS.
<b>Shipping</b>	The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below. *Small pack size (-SP) is shipped with polar packs. Upon receipt, store it immediately at -20 to -70 °C
<b>Stability &amp; Storage</b>	<b>Use a manual defrost freezer and avoid repeated freeze-thaw cycles.</b> <ul style="list-style-type: none"> <li>• 12 months from date of receipt, -20 to -70 °C as supplied.</li> <li>• 1 month, 2 to 8 °C under sterile conditions after reconstitution.</li> <li>• 6 months, -20 to -70 °C under sterile conditions after reconstitution.</li> </ul>

## BACKGROUND

Receptors for the Fc region of IgG (Fc $\gamma$ Rs) are members of the Ig superfamily that function in the activation or inhibition of immune responses such as degranulation, phagocytosis, ADCC (antibody-dependent cellular toxicity), cytokine release, and B cell proliferation (1-3). The Fc $\gamma$ Rs have been divided into three classes based on close relationships in their extracellular domains; these groups are designated Fc $\gamma$ RI (also known as CD64), Fc $\gamma$ RII (CD32), and Fc $\gamma$ RIII (CD16). Each group may be encoded by multiple genes and exist in different isoforms depending on species and cell type. The CD64 proteins are high affinity receptors (~10<sup>-8</sup>-10<sup>-9</sup> M) capable of binding monomeric IgG, whereas the CD16 and CD32 proteins bind IgG with lower affinities (~10<sup>-6</sup>-10<sup>-7</sup> M) only recognizing IgG aggregates surrounding multivalent antigens (1, 4). Fc $\gamma$ Rs that deliver an activating signal either have an intrinsic immunoreceptor tyrosine-based activation motif (ITAM) within their cytoplasmic domains or associate with one of the ITAM-bearing adapter subunits, Fc $\gamma$ R $\gamma$  or  $\zeta$  (3, 5). The only inhibitory member in human and mouse, Fc $\gamma$ RIIB, has an intrinsic cytoplasmic immunoreceptor tyrosine-based inhibitory motif (ITIM). The coordinated functioning of activating and inhibitory receptors is necessary for successful initiation, amplification, and termination of immune responses (5). Mouse CD16 is encoded by a single gene. The protein product is a type I transmembrane protein having two extracellular Ig-like domains. It is expressed on a variety of myeloid and lymphoid cells (4) and associates with Fc $\gamma$ R $\gamma$  to deliver an activating signal upon ligand binding (5). Mouse CD32 is closely related to mouse CD16 throughout its extracellular domain (95% amino acid sequence identity), but has a divergent cytoplasmic domain and functions as an inhibitory receptor. Together these proteins constitute an activating/inhibiting receptor pair to regulate immune responses (5).

### References:

1. van de Winkel, J. and P. Capes (1993) *Immunol. Today* **14**:215.
2. Raghaven, M. and P. Bjorkman (1996) *Annu. Rev. Cell Dev. Biol.* **12**:181.
3. Ravetch, J. and S. Bolland (2001) *Annu. Rev. Immunol.* **19**:275.
4. Takai, T. (2002) *Nature Rev. Immunol.* **2**:580.
5. Ravetch, J. and L. Lanier (2000) *Science* **290**:84.